Skip to main content
padlock icon - secure page this page is secure

Transcytosis of Mesoporous and Hollow Silica Nanoparticles from Endothelial Cells to Cancer Cells

Buy Article:

$106.34 + tax (Refund Policy)

Nanoparticles have been widely researched for delivering drugs into tumor tissue for increase of therapeutic effect and decrease of drug toxicity. Passive targeting via enhanced permeation and retention (EPR) effect and active targeting with conjugation of targeting ligands are considered as two mostly used targeting strategies for nanoparticles targeting. In this research, we found an alternative way for delivering of the nanoparticles without targeting ligands into tumor cells by transcytosis across endothelial cells. The endocytosis for PEGylated mesoporous and hollow silica nanoparticles (PEG-MHSNs) into human umbilical vein endothelial cells (HUVEC) was caveolae-mediated pathway, and that for two cancer cell lines HepG2 and U251 cancer cells was via clathrin-mediated pathway. Importantly, PEG-MHSNs could transcytose across HUVEC monolayer and endocytose into cancer cells. It may provide a promising pathway for drug delivery.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: August 1, 2017

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more